Syndax Pharmaceuticals Inc (SNDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.81 is considered Undervalued compared with the five-year average of -7.05. The fair price of Syndax Pharmaceuticals Inc (SNDX) is between 131.33 to 149.86 according to relative valuation method. Compared to the current price of 22.14 USD , Syndax Pharmaceuticals Inc By Undervalued By 83.14%.

Relative Value

Fair Zone

131.33-149.86

Current Price：22.14

83.14%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Syndax Pharmaceuticals Inc (SNDX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Syndax Pharmaceuticals Inc (SNDX) has a current Price-to-Book (P/B) ratio of 16.04. Compared to its 3-year average P/B ratio of 4.77, the current P/B ratio is approximately 236.52% higher. Relative to its 5-year average P/B ratio of 4.27, the current P/B ratio is about 275.89% higher. Syndax Pharmaceuticals Inc (SNDX) has a Forward Free Cash Flow (FCF) yield of approximately -16.80%. Compared to its 3-year average FCF yield of -16.47%, the current FCF yield is approximately 1.98% lower. Relative to its 5-year average FCF yield of -11.30%, the current FCF yield is about 48.67% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SNDX competitors is 138.46, providing a benchmark for relative valuation. Syndax Pharmaceuticals Inc Corp (SNDX.O) exhibits a P/S ratio of 5.81, which is -95.8% above the industry average. Given its robust revenue growth of 794.90%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SNDX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SNDX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SNDX currently overvalued or undervalued?

Syndax Pharmaceuticals Inc (SNDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.81 is considered Undervalued compared with the five-year average of -7.05. The fair price of Syndax Pharmaceuticals Inc (SNDX) is between 131.33 to 149.86 according to relative valuation method. Compared to the current price of 22.14 USD, Syndax Pharmaceuticals Inc is Undervalued By 83.14%.

What is Syndax Pharmaceuticals Inc (SNDX) fair value?

SNDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Syndax Pharmaceuticals Inc (SNDX) is between 131.33 to 149.86 according to relative valuation method.

How does SNDX's valuation metrics compare to the industry average?

The average P/S ratio for SNDX's competitors is 138.46, providing a benchmark for relative valuation. Syndax Pharmaceuticals Inc Corp (SNDX) exhibits a P/S ratio of 5.81, which is -95.80% above the industry average. Given its robust revenue growth of 794.90%, this premium appears sustainable.

What is the current P/B ratio for Syndax Pharmaceuticals Inc (SNDX) as of Mar 03 2026?

As of Mar 03 2026, Syndax Pharmaceuticals Inc (SNDX) has a P/B ratio of 16.04. This indicates that the market values SNDX at 16.04 times its book value.

What is the current FCF Yield for Syndax Pharmaceuticals Inc (SNDX) as of Mar 03 2026?

As of Mar 03 2026, Syndax Pharmaceuticals Inc (SNDX) has a FCF Yield of -16.80%. This means that for every dollar of Syndax Pharmaceuticals Inc's market capitalization, the company generates -16.80 cents in free cash flow.

What is the current Forward P/E ratio for Syndax Pharmaceuticals Inc (SNDX) as of Mar 03 2026?

As of Mar 03 2026, Syndax Pharmaceuticals Inc (SNDX) has a Forward P/E ratio of -11.30. This means the market is willing to pay $-11.30 for every dollar of Syndax Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Syndax Pharmaceuticals Inc (SNDX) as of Mar 03 2026?

As of Mar 03 2026, Syndax Pharmaceuticals Inc (SNDX) has a Forward P/S ratio of 5.81. This means the market is valuing SNDX at $5.81 for every dollar of expected revenue over the next 12 months.

SNDX Valuation